|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer Statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen C and Wang G: Mechanisms of
hepatocellular carcinoma and challenges and opportunities for
molecular targeted therapy. World J Hepatol. 7:1964–1970. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Schwartz M and Mazzaferro V:
Resection and liver transplantation for hepatocellular carcinoma.
Semin Liver Dis. 25:181–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Poon RT: Prevention of recurrence after
resection of hepatocellular carcinoma: A daunting challenge.
Hepatology. 54:757–759. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coffelt SB, Hughes R and Lewis CE:
Tumor-associated macrophages: Effectors of angiogenesis and tumor
progression. Biochim Biophys Acta. 1796:11–18. 2009.PubMed/NCBI
|
|
6
|
Quatromoni JG and Eruslanov E:
Tumor-associated macrophages: Function, phenotype, and link to
prognosis in human lung cancer. Am J Transl Res. 4:376–389.
2012.PubMed/NCBI
|
|
7
|
Esser N, Legrand-Poels S, Piette J, Scheen
AJ and Paquot N: Inflammation as a link between obesity, metabolic
syndrome and type 2 diabetes. Diabetes Res Clin Pract. 105:141–150.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang YC, He F, Feng F, Liu XW, Dong GY,
Qin HY, Hu XB, Zheng MH, Liang L, Feng L, et al: Notch signaling
determines the M1 versus M2 polarization of macrophages in
antitumor immune responses. Cancer Res. 70:4840–4849. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mantovani A, Sica A, Sozzani S, Allavena
P, Vecchi A and Locati M: The chemokine system in diverse forms of
macrophage activation and polarization. Trends Immunol. 25:677–686.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang HW and Joyce JA: Alternative
activation of tumor-associated macrophages by IL-4: Priming for
protumoral functions. Cell Cycle. 9:4824–4835. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang X, Liang L, Zhang XF, Jia HL, Qin Y,
Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, et al: MicroRNA-26a
suppresses tumor growth and metastasis of human hepatocellular
carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology.
58:158–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cho HJ, Kim SS, Ahn SJ, Park SY, Park JH,
Kim JK, Wang HJ, Cheong JY and Cho SW: Low serum interleukin-6
levels as a predictive marker of recurrence in patients with
hepatitis B virus related hepatocellular carcinoma who underwent
curative treatment. Cytokine. 73:245–252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jang JW, Oh BS, Kwon JH, You CR, Chung KW,
Kay CS and Jung HS: Serum interleukin-6 and C-reactive protein as a
prognostic indicator in hepatocellular carcinoma. Cytokine.
60:686–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ohishi W, Cologne JB, Fujiwara S, Suzuki
G, Hayashi T, Niwa Y, Akahoshi M, Ueda K, Tsuge M and Chayama K:
Serum interleukin-6 associated with hepatocellular carcinoma risk:
A nested case-control study. Int J Cancer. 134:154–163. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ataie-Kachoie P, Pourgholami MH and Morris
DL: Inhibition of the IL-6 signaling pathway: A strategy to combat
chronic inflammatory diseases and cancer. Cytokine Growth Factor
Rev. 24:163–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th Edition of the AJCC Cancer Staging
Manual and the Future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carr BI: Hepatocellular carcinoma: Current
management and future trends. Gastroenterology. 127(5): Suppl
1:S218–S124. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen L, Zhang Q, Chang W, Du Y, Zhang H
and Cao G: Viral and host inflammation-related factors that can
predict the prognosis of hepatocellular carcinoma. Eur J Cancer.
48:1977–1987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL,
Wu JC, Lee PC, Chi CW, Lui WY and Lee SD: Evaluation of
interleukin-6, interleukin-10 and human hepatocyte growth factor as
tumor markers for hepatocellular carcinoma. Eur J Surg Oncol.
33:208–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mosser DM and Zhang X: Interleukin-10: New
perspectives on an old cytokine. Immunol Rev. 226:205–218. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren Y, Poon RT, Tsui HT, Chen WH, Li Z,
Lau C, Yu WC and Fan ST: Interleukin-8 serum levels in patients
with hepatocellular carcinoma: Correlations with
clinicopathological features and prognosis. Clin Cancer Res.
9:5996–6001. 2003.PubMed/NCBI
|
|
22
|
Zhou H, Huang H, Shi J, Zhao Y, Dong Q,
Jia H, Liu Y, Ye Q, Sun H, Zhu X, et al: Prognostic value of
interleukin 2 and interleukin 15 in peritumoral hepatic tissues for
patients with hepatitis B-related hepatocellular carcinoma after
curative resection. Gut. 59:1699–1708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hunter CA and Jones SA: IL-6 as a keystone
cytokine in health and disease. Nat Immunol. 16:448–457. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ataie-Kachoie P, Pourgholami MH,
Richardson DR and Morris DL: Gene of the month: Interleukin 6
(IL-6). J Clin Pathol. 67:932–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bollrath J, Phesse TJ, von Burstin VA,
Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T,
Canli O, Schwitalla S, et al: gp130-mediated Stat3 activation in
enterocytes regulates cell survival and cell-cycle progression
during colitis-associated tumorigenesis. Cancer cell. 15:91–102.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kujawski M, Kortylewski M, Lee H, Herrmann
A, Kay H and Yu H: Stat3 mediates myeloid cell-dependent tumor
angiogenesis in mice. J Clin Invest. 118:3367–3377. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang XH, Liu BR, Qu B, Xing H, Gao SL, Yin
JM, Wang XF and Cheng YQ: Silencing STAT3 may inhibit cell growth
through regulating signaling pathway, telomerase, cell cycle,
apoptosis and angiogenesis in hepatocellular carcinoma: Potential
uses for gene therapy. Neoplasma. 58:158–171. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Soresi M, Giannitrapani L, D'Antona F,
Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N and
Montalto G: Interleukin-6 and its soluble receptor in patients with
liver cirrhosis and hepatocellular carcinoma. World J
Gastroenterol. 12:2563–2568. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanazaki K, Kajikawa S, Shimozawa N,
Mihara M, Shimada K, Hiraguri M, Koide N, Adachi W and Amano J:
Survival and recurrence after hepatic resection of 386 consecutive
patients with hepatocellular carcinoma. J Am Coll Surg.
191:381–388. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Poon RT, Fan ST, Lo CM, Liu CL and Wong J:
Long-term survival and pattern of recurrence after resection of
small hepatocellular carcinoma in patients with preserved liver
function: Implications for a strategy of salvage transplantation.
Ann Surg. 235:373–382. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shiina S, Tateishi R, Arano T, Uchino K,
Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, et al:
Radiofrequency ablation for hepatocellular carcinoma: 10-year
outcome and prognostic factors. Am J Gastroenterol. 107:569–577.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sheng T, Wang B, Wang SY, Deng B, Qu L, Qi
XS, Wang XL, Deng GL and Sun X: The relationship between serum
interleukin-6 and the recurrence of hepatitis B virus related
hepatocellular carcinoma after curative resection. Medicine
(Baltimore). 94:e9412015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Strassmann G, Fong M, Kenney JS and Jacob
CO: Evidence for the involvement of interleukin 6 in experimental
cancer cachexia. J Clin Invest. 89:1681–1684. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He G, Dhar D, Nakagawa H, Font-Burgada J,
Ogata H, Jiang Y, Shalapour S, Seki E, Yost SE, Jepsen K, et al:
Identification of liver cancer progenitors whose malignant
progression depends on autocrine IL-6 Signaling. Cell. 155:384–396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim KH and Choi YK: Long-term survival
after resection of hepatocellular carcinoma. Korean J Hepatobiliary
Pancreat Surg. 16:98–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen TW, Chu CM, Yu JC, Chen CJ, Chan DC,
Liu YC and Hsieh CB: Comparison of clinical staging systems in
predicting survival of hepatocellular carcinoma patients receiving
major or minor hepatectomy. Eur J Surg Oncol. 33:480–487. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Metwaly HA, Al-Gayyar MM, Eletreby S,
Ebrahim MA and El-Shishtawy MM: Relevance of serum levels of
interleukin-6 and Syndecan-1 in patients with hepatocellular
carcinoma. Sci Pharm. 80:179–188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Erickson-Miller CL, Chadderton A, Gibbard
A, Kirchner J, Pillarisetti K, Baker K, Pandite L, El-Hariry I,
Mostafa Kamel Y, Liu Y, et al: Thrombopoietin receptor levels in
tumor cell lines and primary tumors. J Oncol. 2010:1353542010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Amano H, Tashiro H, Oshita A, Kobayashi T,
Tanimoto Y, Kuroda S, Tazawa H, Itamoto T, Asahara T and Ohdan H:
Significance of platelet count in the outcomes of hepatectomized
patients with hepatocellular carcinoma exceeding the milan
criteria. J Gastrointest Surg. 15:1173–1181. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kaneko K, Shirai Y, Wakai T, Yokoyama N,
Akazawa K and Hatakeyama K: Low preoperative platelet counts
predict a high mortality after partial hepatectomy in patients with
hepatocellular carcinoma. World J Gastroenterol. 11:5888–5892.
2005. View Article : Google Scholar : PubMed/NCBI
|
